#ECTRIMS2022 – New Analyses Say Ublituximab Is Superior to Aubagio
The experimental therapy ublituximab works better than the approved treatment Aubagio (teriflunomide) at easing disability independently of relapses,…
Articles by Marta Figueiredo, PhD
#ECTRIMS2022 – Analyses Weigh Stem Cell Transplant Versus DMTs
Autologous hematopoietic stem cell transplant (aHSCT) is superior to Gilenya (fingolimod) and Tysabri (natalizumab) at preventing relapses and…
#ECTRIMS2022 – 2 Brain Lesion Types Linked to Greater Disability
Recently diagnosed multiple sclerosis (MS) patients with two forms of chronic active brain lesions — slowly expanding lesions (SELs)…
#ECTRIMS2022 – Tecfidera Lowers Risk of 1st Symptoms in RIS in Trial
Treatment with Tecfidera (dimethyl fumarate) significantly reduces the risk of experiencing the first multiple sclerosis (MS) symptoms in…
#ECTRIMS2022 – Relapse-free Progression Evident in Pediatric MS
Disability progression in the absence of relapses is less common in children and adolescents with multiple sclerosis (MS) than…
#ECTRIMS2022 – Long-term Gilenya Reduces Pediatric Relapses
Long-term treatment with Gilenya (fingolimod) continues to be safe and lower the rate of relapses in children and adolescents with…
#ECTRIMS2022 – Study Examines Ocrevus Use Before, During Pregnancy
Treatment with Ocrevus (ocrelizumab) before or during pregnancy does not seem to increase the risk of major pregnancy or…
#ECTRIMS2022 – 2-year Ocrevus Effective for Early MS Patients: Data
Nearly 80% of people with early-stage relapsing-remitting multiple sclerosis (RRMS) show no evidence of disease activity after two years…
Delayed Ocrevus Infusion May Increase MRI-based RRMS Risk
An extended interval between maintenance doses of Ocrevus (ocrelizumab) may increase the risk of MRI-based disease activity in people with…
Long-term Ponvory Treatment Safe, Effective in RRMS, Trial Data Show
Long-term treatment with Ponvory (ponesimod) safely and effectively reduces the rate of relapses, slows disability worsening, and prevents brain…
TRE-515 Appears to Block Immune Cell Attacks in Mouse Study
An experimental oral therapy called TRE-515 significantly reduced disease severity and the growth of the abnormal immune cells that drive…
For Pregnant MS Patients, No Added Risk of Infant Growth Deficits: Study
Women with multiple sclerosis (MS) are not at a higher risk of their babies having growth deficits during pregnancy…
MS Spasticity Therapy Baclofen Helps to Repair Myelin: Early Study
Baclofen, an approved therapy for spasticity in multiple sclerosis (MS) patients, promoted the repair of myelin — the…
Oral Therapy TRE-515 Wins Orphan Drug Status for Optic Neuritis in US
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Trethera Corporation’s experimental oral therapy TRE-515…
Study Uncovers How Interferon-beta May Be Helping to Treat MS
Researchers have discovered how interferon-beta, a common treatment for multiple sclerosis (MS), may be effective for people with the…
CNM-Au8 Lessens Vision Problems in RRMS Patients in Phase 2 Trial
CNM-Au8, Clene Nanomedicine’s experimental oral therapy, safely and effectively improves vision and neurological function in adults with stable…
Calyx, Qynapse to Expand Use of Neuroimaging AI Tools
Calyx and Qynapse have joined forces to expand the use of artificial intelligence (AI)-based neuroimaging tools in clinical…
Higher COVID-19 Risk Tied to 2 MS Therapies, Even With Vaccination
Fully vaccinated multiple sclerosis (MS) patients who are treated with Ocrevus (ocrelizumab) or Gilenya (fingolimod) have a significantly higher…
NICE Updates Its Guidelines for MS Management
The National Institute for Health and Care Excellence (NICE) in England has updated its guidelines for the diagnosis and…
Biogen Secures Tecfidera Patent in EU Until 2028; Generics Not Likely
Biogen has secured a new patent in Europe covering the use of its oral therapy Tecfidera (dimethyl fumarate) for…
Find Therapeutics, SATT Conectus Team to Develop New MS Therapy
Find Therapeutics and SATT Conectus have joined forces to develop a promising therapy for multiple sclerosis (MS)…
PoNS Device Improves Walking Skills Early On, New Data Show
Using the portable neuromodulation stimulator (PoNS) device during a targeted exercise program significantly improves walking skills in people with…
Phase 1/2 Trial Is Testing Cutting-edge Immunotherapy in MS Patients
A Phase 1/2 clinical trial is evaluating the safety and effectiveness of a cutting-edge immunotherapy called extracorporeal photopheresis in people…
Lyvispah, Dissolvable Form of Baclofen, Now Available in US
Lyvispah — a dissolvable granular formulation of baclofen — is now commercially available in the U.S. for adults and adolescents,…
Mayzent and Kesimpta Gaining Ground as MS Treatments in Canada
Novartis’ Mayzent (siponimod) and Kesimpta (ofatumumab) are gaining ground among multiple sclerosis (MS) therapies in Canada, according to…
‘Silent Progression’ in Relapsing MS Linked to Significant Brain Atrophy
People with relapsing multiple sclerosis who have disability progression, but no clinical relapses, show significantly faster brain shrinkage, or…
High Adherence to Rebif Seen With RebiSmart Use, Chats With Doctor
Regular feedback from doctors about dosing data and health status is associated with high and sustained treatment adherence to…
Progressive MS, Degree of Disability Increase Infection Risk
People with progressive forms of multiple sclerosis (MS) and those with greater MS-related disability have a significantly greater risk…
Copaxone Appears Safe for Infants Whose Mothers Breastfeed: Study
Taking Copaxone (glatiramer acetate), an approved therapy for relapsing forms of multiple sclerosis (MS), while breastfeeding does not appear to be…
Stress-reducing Activities Linked to Lower Risk of Depression, Fatigue
Multiple sclerosis (MS) patients undertaking stress-reducing activities — particularly physical and relaxation activities or meditation — at least once…